Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | F7 | P08709 | 15/20 | 0.42 |
| ▸ | F3 | P13726 | 12/20 | 0.42 |
| ▸ | F10 | P00742 | 7/20 | 0.41 |
| ▸ | F2 | P00734 | 5/20 | 0.41 |
| ▸ | F11 | P03951 | 2/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8346171 | 0.86 | L3MBTL1 (0.40) | ALDH1A1MAPK1F7F3F10 | |
| SCHEMBL4151760 | 0.85 | ALDH1A1 (0.44) | ALDH1A1MAPTMAPK1F7F3 | |
| SCHEMBL4598954 | 0.84 | F7 (0.44) | ALDH1A1MAPTMAPK1F7F3 | |
| SCHEMBL5038029 | 0.84 | ALDH1A1 (0.43) | ALDH1A1MAPTMAPK1F7F3 | |
| SCHEMBL2535837 | 0.83 | NPSR1 (0.44) | ALDH1A1MAPTF7F3F10 | |
| SCHEMBL5133590 | 0.77 | NPSR1 (0.49) | F7F3F10F2F11 | |
| SCHEMBL13085679 | 0.77 | TSHR (0.46) | ALDH1A1MAPTMAPK1F7F3 | |
| Hydrochloric Acid SCHEMBL21494509 | 0.76 | PDE4A (0.47) | F7F3F10F2F11 | |
| SCHEMBL27877166 | 0.76 | ALDH1A1 (0.46) | ALDH1A1MAPK1PDE4APDE4BPDE4C | |
| SCHEMBL187559 | 0.75 | CYP2C19 (0.52) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456195-B2 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1594505-A4 | PHENYLGLYCINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1910298-A2 | PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | Brystol-Myers Squibb Company (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007002313-A2 | PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
| US-7122559-B2 | Phenylglycine derivatives useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1594505-A2 | PHENYLGLYCINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20040204412-A1 | Phenylglycine derivatives useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | disclosed |
| WO-2004072101-A2 | PHENYLGLYCINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-26 | — | — | WO | disclosed |
| WO-2004072101-A2 | PHENYLGLYCINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204412-A1 | Phenylglycine derivatives useful as serine protease inhibitors | F7, SERPINE1, HABP2 | ALDH1A1 3767/4885MAPT 4322/4885MAPK1 2296/4885 |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | F12, F11, F7 | ALDH1A1 2963/4885MAPT 1601/4885MAPK1 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.